Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 25 Hot Line Discussion: VICTOR: Vericiguat in Heart Failure
Author(s): Harriette Van Spall , Faiez Zannad Added: 7 months ago
ESC Congress 2025 - Vericiguat did not reduce the risk of cardiovascular mortality and hospitalization in heart failure with reduced ejection fraction, fewer cardiovascular deaths and all-cause deaths were observed.Host, Dr Harriette Van Spall (McMaster University, CA) is joined on-site at ESC Congress 2025 in Madrid by Dr Faiez Zannad (University of Lorraine, FR) to discuss pivotal results from… View more

Prevention & Chronic Conditions

Heart Failure
ESC HF 25: The VELOCITY Study
Author(s): Stephen J Greene Added: 11 months ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an… View more

Heart Failure
VICTOR Trial: Vericiguat Shows No Benefit for Primary Endpoint in Stable HFrEF
Added: 7 months ago Source:  Radcliffe Cardiology
Results from the Phase III VICTOR trial, presented at the European Society of Cardiology (ESC) Congress 2025 and published in The Lancet, show that vericiguat did not meet its primary endpoint in patients with chronic, stable heart failure with reduced ejection fraction (HFrEF).¹˒²Vericiguat is an oral, once-daily stimulator of soluble guanylate cyclase (sGC), an enzyme in the nitric oxide… View more

Guidelines & Statements

Heart Failure
ESC 25: The VICTOR & VICTORIA Pooled Analysis
Author(s): Javed Butler Added: 7 months ago
ESC Congress 2025 - Vericiguat significantly reduced risks of CV mortality and HF hospitalisations, as well as all-cause mortality across both the VICTOR and VICTORIA Trial.Dr JavedButler (Baylor Scott & White Health, Dallas, US) joins us to discuss findings from a pooled analysis of the recent VICTOR and VICTORIA trials, with data from 11155 participants with heart failure with reduced ejection… View more

Heart Failure
ESC 2025 Hot Line & Late-Breaking Collection
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 8 months ago
Dive into our coverage of ESC Congress 2025 for groundbreaking trial results and discussions with expert faculty.Watch ourView From the Thoraxcenterseries for practice-focused reviews of the most anticipated trials from interventional experts,Prof Nicolas Van MieghemandDr Joost Daemen. Watch our Wrap-Upseries led byDr Mirvat Alasnag summarising the key take-aways from each day of the congress.For… View more

Imaging & Diagnostics

Intervention
EPCs and Innovative Strategies for Endothelial Dysfunction in Heart Failure
Author(s): Eugenio Carulli , Marialuisa Sveva Marozzi , Maria Cristina Carella , et al Added: 8 months ago

Prevention & Chronic Conditions

Heart Failure
Pharmacological Therapy of HFrEF in 2025
Author(s): Massimo Mapelli , Filippo Maria Rubbo , Simona Costantino , et al Added: 8 months ago

Heart Failure
Late-Breaking Sessions Revealed for HSFA Annual Scientific Meeting 2025
Added: 7 months ago Source:  HFSA 2025 Scientific Programme
HSFA Annual Scientific Meeting 2025 has released its late-breaking clinical research sessions which are to be presented in September 2025.The meeting is set to take place from the 26th to 29th September 2025 at Minneapolis Convention Center in Minnesota, US.Access the full programme here.Late Breaking Clinical Research 1: Devices and CardiomyopathiesSunday 28th September, 09:00am – 10:30am (CDT… View more

Vascular Disease and Surgery

Demographic
Harriette Van Spall
Research Area(s) / Expertise: Job title: Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is aninternationally known cardiologist, research methodologist, and senior scientist.She serves as an Associate Professor of Medicine atMcMaster University, a Senior Scientist at thePopulation Health Research Institute, and Director of Implementation Science at theBaim Institute for Clinical Research in Boston.​Academic historyDr Van Spall completed her BSc and MD at… View more
The Timing for Primary Prevention ICD in the Current Era of Pharmacotherapy
Author(s): Anastasia Shchendrygina , Amin Yehya , Hadi Skouri Added: 9 months ago

Heart Failure